Please enter exact key words
Therapeutic antibody against Frizzled 5

for the Treatment of Ovarian Cancer

Home / Available Projects / Therapeutic antibody against Frizzled 5
Drug Name GPCR-targeted Project 017

Frizzled 5 (FZD5) is highly expressed in ovarian cancer cells, associated with poor prognosis, such as its ligand WNT5a. A humanized monoclonal antibody (mAb) targeting FZD5 is being developed for the treatment of ovarian cancer.

Target Frizzled 5 (FZD5)
Drug Modality Monoclonal antibody
Indication Ovarian cancer
Product Category Biologic
Mechanism of Action Wnt signaling pathway stimulants
Status Discovery
Patent Granted

More Detail Available Upon Request

We look forward to hearing from you.

Our customer service representatives are available 24 hours a day, from Monday to Sunday Online Inquiry

Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.

Protheragen Inc.